Search Results
Sorafenib vs placebo in treatment-naïve FLT3-ITD AML
FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia
Acute Myeloid Leukemia: Incorporating Novel Treatment Approaches into Clinical Pathways
COSTEM AML highlights: SCT & MRD status, sorafenib maintenance & gilteritinib in FLT3+ AML
Does gilteritinib improve outcome post-midostaurin or -sorafenib treatment?
FLT3 Inhibitors in the Therapy of Acute Myeloid Leukemia
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
QuANTUM-First: association between FLT3-ITD-specific MRD clearance and survival in patients with AML
Quizartinib for frontline FLT3-ITD+ AML: updated results from the QuANTUM-First trial
What Is FLT3-Mutated Acute Myeloid Leukemia?
Sorafenib maintenace improves outcomes for FLT3-ITD AML
DECISION Trial: Support for Sorafenib
